People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adagio Medical, Inc. | — | Healthtech | Series C | $81.6M | $128.1M | 2020 |
| Forte Biosciences, Inc. | — | Biotechnology | Series B | $25.2M | $771.4M | 2018 |
Tuan Huynh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tuan Huynh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Olav B. Bergheim | 1 | 13 |
| Hugh B. Neuharth | 1 | 7 |
| Zach Scheiner | 1 | 6 |
| James Cox | 1 | 6 |
| Paul Wagner | 1 | 3 |
| Olav Bergheim | 1 | 2 |
| MICHAEL ZHAO | 1 | 2 |
| Lawrence Eichenfield | 1 | 2 |
| Hugh Neuharth | 1 | 2 |
| Andrew Wade | 1 | 1 |
| Antony A. Riley | 1 | 1 |
| Paul A. Wagner, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.